

## **Newsletter TI Pharma – number 4, dated 3 November 2005**

**The Council of Ministers has granted the TI Pharma a subsidy of EUR 130 m for the next four years. After filing the business plan in July this was a crucial step for the realization of the TI Pharma. The decision still needs to be ratified by the parliament during the "algemene beschouwingen", which is expected in November. Work is in process on building the organization and making a first strategic research plan. Our objective is to have all partner contracts signed by the end of December, to enable the formal foundation of the TI Pharma as of January 1<sup>st</sup> 2006.**

### **Building the organization**

In the mean time the governance of the Institute has been decided by the preliminary Executive Board on their meeting on October 21:

- Supervisory Board, the highest governing body of the Institute in which all partners are represented, to be chaired by Sybolt Noorda.
- Executive Board, will work closely with the Management Team, and will consist of representatives of all groups among the partners: Ton Rijnders - chairman, Les Turski (both large industry), Arthur Lahr, Joost Holthuis (both small industry), Lou de Leij (UMC's), Rob Leurs, Frans Russel (both preclinical research).
- Management Team will consist of Daan Crommelin (Scientific Director) and Victor Nickolson (Managing Director)
- International Scientific Review Committee will review the performance and quality of the Institute on a (bi)annual basis
- A Board of Trustees will formalize the role of TI Pharma's societal stakeholders: the Government, FIGON, ZonMw, and others

The Institute has welcomed many new prospective partners who have signed a Letter of Intent: Altana, GSK, BioMade, Fuji Photo, Cardialysis, Pharming, Nobilon and TNO.

Leiden Bio-Science Park was chosen as the location of the relatively small administrative centre of the Institute, of which most of the activities will be located at the premises of the participating industrial and academic partners.

### **Building the strategic research plan**

Mid September the first working groups for building the strategic research plan have started. Members of the working groups are the Academic and Industrial Quarter Makers (see table below for their names, contact person/chairperson per group is indicated in bold). Per Theme and Discipline this small group of representatives from Academia and Industry has been asked to provide a first outline of the main objectives per Theme or Discipline as well as a list of potential projects which will lead to meeting these objectives. Formats and boundary conditions for projects were distributed and explained, such as meeting the 1:1:2 funding rule (participation from industry : academia : government) also on project level and having at least 3 partners involved in a project consortium.

The Academic Quarter Makers have been asked to ensure that the most excellent research groups in each field are mobilized for the execution of the research.

The working groups have November the 5<sup>th</sup> as the deadline for their output after which the (preliminary) Management Team and Executive Board of the Institute will use these outputs to make a first coherent strategic research plan. Most likely the full

budget will not be filled in as of January 1<sup>st</sup> since the TI Pharma aims for top quality in the research projects. However, the aim is and will be to start with as many projects as possible, but also offer room for new projects to start in the course of 2006, or later.

An IP guideline has been accepted by the preliminary Executive Board, and this guideline will be used for the separate IP arrangements that will be made for each project.

The FIGON working group

The Quarter Makers for each Theme and Discipline are listed in the table below.

<b>Themes</b>	<b>Industry interest</b>	<b>Quarter Makers (working group chairman/women in bold)</b>
(Auto-) Immune Diseases	Pharma Bio-research Organon IQ Corporation Solvay Numico	W. Timmerman (PBR) Dr. A. Boots (Organon) Dr. H. Groen (IQ Corporation) <b>Dr.J. Garssen (Numico)</b> Prof.dr. D.Postma (RUG) Prof.dr. F.Nijkamp (UU)
Cardio-vascular Diseases	Octoplus Pharma Bio-research Crucell Solvay Organon	Dr. J. Holthuis (Octoplus) A. van Vliet (PBR) Prof.dr. J. Goudsmit (Crucell) Dr. J. Antel (Solvay) Dr. C. Long (Organon) Prof.dr. T. van Berkel (UL) <b>Prof.dr. J. Smits (UM)</b>
Neoplastic Diseases	Octoplus Pepscan J&J Organon (part)	Dr. J. Holthuis (Octoplus) Dr. R. Meloen (Pepscan) Dr. J. Arts (J&J) Dr. M. van Duin (Organon) <b>Prof.dr.A. Berns (NKI)</b> <b>Prof.dr. E. de Vries (RUG)</b>
Infectious Diseases	Pharma Bio-research OctoPlus Crucell IQ Corporation Solvay	Dr. A. van Vliet (PBR) Dr. J.Holthuis (Octoplus) Prof.dr. J. Goudsmit (Crucell) <b>Dr. H. Groen (IQ Corporation)</b> D. Leyssius (Solvay) Prof.dr. A. Osterhaus (EUR) Prof.dr. R.Sauerwein (RUN)
CNS Diseases	Pharma Bio-research Solvay Organon J&J Numico	W. Timmerman (PBR) Prof.dr. C. Kruse (Solvay) Dr. D.Hill (Organon) Dr. W. Drinkenburg (J&J) Dr. E. van der Beek (Numico) <b>Prof.dr. J. van Ree (UU)</b> Prof.dr. E.R. de Kloet (UL)
Efficiency Analysis of the Process of Drug Discovery, Development and Utilization	Solvay t.b.d.	drs. A. Kalis (CBG) Prof.dr. C. Kruse (Solvay) Dr. M. van der Graaff (NEFARMA) <b>Prof.dr. B. Leufkens (UU)</b> Prof.dr. F.Rutten (EUR)

<b>Disciplines</b>	<b>Industry interest</b>	<b>Quarter Maker</b>
Therapeutic Target Finding, Validation & Animal Models	Organon Solvay Pepscan J&J	Dr. A. Garritsen (Organon) Dr. C. Ronken (Solvay) Dr. J. Garssen (Numico) Dr. D. Moechars (J&J) Prof.dr. A. IJzerman (UL) <b>Prof.dr. R. Adan (UU)</b>
Lead Selection, In-Silico and PK/PD Modeling	Pharma Bio-research Organon Solvay Numico	Dr. B. Oosterhuis (PBR) Prof.dr. C. van Boeckel (Organon) Dr. Y. Karimi (Solvay) Dr. R. Meloen (Pepscan) Prof.dr. W. Quax (RUG) <b>Prof.dr. M. Danhof (UL)</b>
Predictive Drug Disposition and Toxicology	Organon Solvay J&J	Dr. D. van den Dobbelsteen (Organon) Dr. M. Hesselink (Solvay) Prof.dr. G. Groothuis (RUG) <b>Prof.dr. N. Vermeulen (VU)</b>
Biomarkers and Bio-sensing	Pharma Bio-research Solvay J&J Organon	Dr. M. Nemansky (PBR) Dr. J. Venema (Solvay) Dr. W. Drinkenburg (J&J) Dr. M. Honing (Organon) <b>Prof.dr. R. Bischof (RUG)</b> Prof.dr. J. van der Greef (TNO Pharma)
Drug Formulation, Delivery and Targeting	OctoPlus Pharma Bio-research Organon Solvay Fujifilm	Dr. L. de Leede (Octoplus) Dr. B. Oosterhuis (PBR) <b>Prof.dr. H. Vromans (Organon)</b> Dr. H. Dinter-Heidorn (Solvay) Dr.ir. J. Bouwstra (Fujifilm) Prof.dr. D. Crommelin (UU) Prof.dr. F. Russel (RUN)
Pharmaceutical Production Technologies	Crucell OctoPlus Organon Solvay	Prof.dr. J. Goudsmit (Crucell) J. Medema (Solvay) F. Kaspersen (Organon) <b>Prof. E. Frijlink (RUG)</b> Prof.dr. D. Crommelin
Molecular informatics	Organon Solvay J&J	Dr. C. van Schaijk (Organon) Dr. C. Thaete (Solvay) <b>Prof.dr. A. IJzerman (UL)</b>